好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

2026 Annual Meeting | S1 - New Perspectives on Alzheimer's Therapeutics

Sunday 04/19/26
01:00 PM - 03:00 PM CDT Add To Calendar
McCormick Place West | W196c
This program will be presented both in-person and online
This program will be available in the meeting's On Demand product.
Scientific Platform Session
Irina Skylar-Scott, MD, James E. Eaton III, MD
Aging, Dementia, and Behavioral Neurology
2.00 CME credits

Program Materials

Event Timeline
01:00 PM - 01:24 PM CDT Speaker 2026 Potamkin Prize for Research in Pick's, Alzheimer's, and Related Diseases: This award recognizes major contributions to the understanding of the causes, prevention, treatment, and cure for Pick's, Alzheimer's, and related diseases
Timothy M. Miller, MD, PhD
01:24 PM - 01:36 PM CDT Abstract 003 - The Effects of Lecanemab Treatment on Soluble CSF Aß Protofibrils (PF) in Clarity AD
Kanta Horie, PhD
01:36 PM - 01:48 PM CDT Abstract 004 - Clinical Profile for Lecanemab Subcutaneous Formulation for Treatment Initiation and Maintenance in Early Alzheimer’s Disease (AD)
Sharon Cohen, MD
01:48 PM - 02:00 PM CDT Abstract 005 - The Lecanemab Clarity AD Open-label Extension in Early Alzheimer’s Disease: Initial Findings from the 48-month Analysis
Christopher van Dyck, MD
02:00 PM - 02:12 PM CDT Abstract 006 - Estimating the 10-Year Time-savings Benefits of Lecanemab Treatment
Suzanne Hendrix, PhD
02:12 PM - 02:24 PM CDT Abstract 007 - Real-world Delays in Anti-amyloid Therapy Initiation Following Diagnosis of Early-stage Alzheimer’s Disease
Michael H. Rosenbloom, MD, FAAN
02:24 PM - 02:36 PM CDT Abstract 008 - Effects of Semaglutide on Alzheimer’s Disease-related Biological Processes: Results from a Biofluid Biomarker and Multiomics Immunophenotyping Phase 3 Study in Patients with Early Alzheimer’s Disease After 12 Weeks of Treatment
Dylan M. Belmont-Rausch, PhD
02:36 PM - 02:48 PM CDT Abstract 009 - Safety and ARIA Analyses of Oral Anti-amyloid Oligomer Agent Valiltramiprosate in APOE4/4 Homozygotes with Early Alzheimer’s Disease (AD): Results of the Phase 3 78-week APOLLOE4 Trial
Earvin Liang, PhD
02:48 PM - 03:00 PM CDT Abstract 010 - Inhibition of Amyloid-ß and a-Synuclein Oligomer-induced NLRP3 Inflammasome Activation by NDGA in Microglia: A Promising Anti-inflammatory Strategy for Neurodegeneration
Anh Hoang
Faculty Disclosures
Irina Skylar-Scott, MD An immediate family member of Dr. Skylar-Scott has received personal compensation in the range of $500-$4,999 for serving as a Consultant for 3D Systems. Dr. Skylar-Scott has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for PeerView/Lilly. The institution of an immediate family member of Dr. Skylar-Scott has received research support from The Chan Zuckerberg Initiative. Dr. Skylar-Scott has received research support from Biogen. An immediate family member of Dr. Skylar-Scott has received intellectual property interests from a discovery or technology relating to health care. Dr. Skylar-Scott has received publishing royalties from a publication relating to health care.
James E. Eaton III, MD Dr. Eaton has received personal compensation in the range of $0-$499 for serving as a Consultant for Uniqure. Dr. Eaton has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Law Practices. Dr. Eaton has received personal compensation in the range of $0-$499 for serving as a Speaker with Can Do MS.
Timothy M. Miller, MD, PhD Dr. Miller has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ionis Pharmaceuticals. Dr. Miller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Miller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arbor Bio. Dr. Miller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biomarin. The institution of Dr. Miller has received research support from Ionis Pharmaceuticals . Dr. Miller has received intellectual property interests from a discovery or technology relating to health care. Dr. Miller has received intellectual property interests from a discovery or technology relating to health care.
Lynn D. Kramer, MD, FAAN Dr. Kramer has received personal compensation for serving as an employee of Eisai Inc. Dr. Kramer has received personal compensation in the range of $1,000,000+ for serving as an officer or member of the Board of Directors for Eisai Co., Ltd..
Christopher van Dyck, MD Dr. van Dyck has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. van Dyck has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. van Dyck has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ono. Dr. van Dyck has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. van Dyck has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerevel. Dr. van Dyck has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB.
David A. Watson, PsyD Dr. Watson has nothing to disclose.
Michael C. Irizarry, MD Dr. Irizarry has received personal compensation for serving as an employee of Eisai, Inc..
Emer MacSweeney No disclosure on file
Isabel Crane Ms. Crane has nothing to disclose.
Kanta Horie, PhD Dr. Horie has received personal compensation for serving as an employee of Eisai Inc.
Suzanne Hendrix, PhD Dr. Hendrix has received personal compensation for serving as an employee of Pentara Corporation. Dr. Hendrix has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pentara Corporation. Dr. Hendrix has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Pentara Corporation. The institution of Dr. Hendrix has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Pentara Corporation. Dr. Hendrix has or had stock in Pentara.
Daryl R. Jones Dr. Jones has received personal compensation for serving as an employee of Eisai.
Manjot Singh, MD Dr. Singh has nothing to disclose.
Kazuhiro Tahara Mr. Tahara has nothing to disclose.
Steven M. Hersch, MD, PhD Dr. Hersch has received personal compensation for serving as an employee of Eisai Inc.. Dr. Hersch has stock in Voyager Therapeutics. The institution of an immediate family member of Dr. Hersch has received research support from NIH. Dr. Hersch has received intellectual property interests from a discovery or technology relating to health care.
Shankar Chinta, PhD Dr. Chinta has nothing to disclose.
Sneha Padmanaban Ms. Padmanaban has nothing to disclose.
Shobha Dhadda Shobha Dhadda has received personal compensation for serving as an employee of Eisai Inc.
Anna Patten No disclosure on file
Natalia Penner, PhD Dr. Penner has received personal compensation for serving as an employee of eisai. Dr. Penner has received personal compensation for serving as an employee of Zentalis. Dr. Penner has received personal compensation for serving as an employee of Biogen. Dr. Penner has stock in Biogen.
Pratik Bhagunde, PhD Dr. Bhagunde has received personal compensation for serving as an employee of Eisai.
Earvin Liang, PhD Dr. Liang has nothing to disclose.
Martin Tolar, MD, PhD Dr. Tolar has received personal compensation for serving as an employee of Alzheon. Dr. Tolar has received intellectual property interests from a discovery or technology relating to health care.
Larisa Reyderman Larisa Reyderman has nothing to disclose.
Samuel Dickson Mr. Dickson has nothing to disclose.
Garrett Duncan, MS Mr. Duncan has received personal compensation for serving as an employee of Pentara Corporation.
John A. Hey, PhD Dr. Hey has received personal compensation for serving as an employee of Alzheon. Dr. Hey has stock in Alzheon. Dr. Hey has stock in Alzheon. Dr. Hey has received intellectual property interests from a discovery or technology relating to health care.
John D. Whetten, MS The institution of Mr. Whetten has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eisai.
Reisa A. Sperling, MD Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AC Immune. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acumen. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alector. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nervgen. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Oligomerix. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Prothena. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ionis. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vaxxinity. An immediate family member of Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. An immediate family member of Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. The institution of Dr. Sperling has received research support from Eli Lilly. The institution of Dr. Sperling has received research support from Eisai. The institution of Dr. Sperling has received research support from NIH.
Susan Abushakra, MD Dr. Abushakra has received personal compensation for serving as an employee of Alzheon Inc.. Dr. Abushakra has stock in Alzheon Inc.. The institution of Dr. Abushakra has received research support from NIH. Dr. Abushakra has received intellectual property interests from a discovery or technology relating to health care.
Sharon Cohen, MD Dr. Cohen has nothing to disclose.
Rosalind McLaine, PA Mrs. McLaine has nothing to disclose.
Susan M. Flint, MS Ms. Flint has received personal compensation for serving as an employee of Alzheon. Ms. Flint has stock in Alzheon.
Pallavi Sachdev No disclosure on file
Julie K. Andersen, PhD The institution of Prof. Andersen has received research support from Buck.
Anh Hoang Miss Hoang has nothing to disclose.
Aidan Power, PhD Dr. Power has received personal compensation for serving as an employee of Alzheon. Dr. Power has stock in Pfizer. Dr. Power has stock in Alzheon.
Sharon Cohen, MD The institution of Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. The institution of Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen.
Mercè Boada Rovira, MD, PhD Dr. Boada Rovira has received personal compensation for serving as an employee of FUNDACIO ACE. ICNA. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GRIFOLS. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ARACLON BIOTECH. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ROCHE. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BIOGEN. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MERCK. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ZAMBON. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GRIFOLS. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ARACLON BIOTECH. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIOGEN. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for LILLY. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MERCK. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ZAMBON. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NOVO NORDISK. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIOIBERICA. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SERVIER. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EISAI. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SCHWABE PHARMA. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ROCHE. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BIOGEN. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for GRIFOLS. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for NUTRICIA. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ARACLON BIOTECH. The institution of Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for SERVIER. Dr. Boada Rovira has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for ZAMBON.
Kazuyoshi Shuta, MSc Mr. Shuta has received personal compensation for serving as an employee of Eisai Co., Ltd..
Anand Rane Mr. Rane has nothing to disclose.
Michael H. Rosenbloom, MD, FAAN Dr. Rosenbloom has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Esai. Dr. Rosenbloom has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Eisai.
Akihiko Koyama No disclosure on file
Marwan N. Sabbagh, MD, FAAN Dr. Sabbagh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genetech=Roche. Dr. Sabbagh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novo Nordisk. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Sabbagh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Synaptogenix. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Signant Health. Dr. Sabbagh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Anavex. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cognito Therapeutics. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Sabbagh has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for CervoMed. Dr. Sabbagh has stock in Neurotau. Dr. Sabbagh has stock in Seq Biomarque. Dr. Sabbagh has stock in uMethod Health. Dr. Sabbagh has stock in Athira. Dr. Sabbagh has stock in Lighthouse Pharmaceuticals. Dr. Sabbagh has stock in Alzheon. The institution of Dr. Sabbagh has received research support from NIH. The institution of Dr. Sabbagh has received research support from ADDF.
Katherine Youmans-Kidder, PhD No disclosure on file
karim bennys, MD Dr. bennys has nothing to disclose.
Michio Kanekiyo, MS Mr. Kanekiyo has received personal compensation for serving as an employee of Eisai Inc. Mr. Kanekiyo has stock in Eisai Co Ltd..
David Li David Li has received personal compensation for serving as an employee of Eisai.
James P. Kesslak, PhD Dr. Kesslak has received personal compensation for serving as an employee of Alzheon.
Jerome A. Barakos, MD Dr. Barakos has nothing to disclose.
Michelle Gee, PhD Dr. Gee has nothing to disclose.
Andrea Schnee, RN Mrs. Schnee has nothing to disclose.
Marie Bentsen Marie Bentsen has received personal compensation for serving as an employee of Novo Nordisk.
Gabriel Martino, MD Dr. Martino has received personal compensation for serving as an employee of Novo Nordisk A/S. Dr. Martino has stock in Novo Nordisk. Dr. Martino has stock in Roche. Dr. Martino has stock in Eli Lilly.
Paul Mystkowski, MD Dr. Mystkowski has received personal compensation for serving as an employee of Novo Nordisk. Dr. Mystkowski has stock in Novo Nordisk.
Kristian S. Frederiksen, MD, PhD Dr. FREDERIKSEN has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer (Nature). Dr. FREDERIKSEN has received research support from AP Møller Fonden. Dr. FREDERIKSEN has received publishing royalties from a publication relating to health care.
Brian Cutler Mr. Cutler has nothing to disclose.
Amaya Zaratiegui, MD Mrs. Zaratiegui has received personal compensation for serving as an employee of Novo Nordisk A/S. Mrs. Zaratiegui has stock in Novo Nordisk A/S.
Lisbeth Carstensen, PhD Ms. Carstensen has received personal compensation for serving as an employee of Novo Nordisk A/S. Ms. Carstensen has stock in Novo Nordisk A/S.
Peter Johannsen, MD Dr. Johannsen has received personal compensation for serving as an employee of Novo Nordisk. Dr. Johannsen has or had stock in Novo Nordisk.
Lotte B. Knudsen, DMSc Dr. Knudsen has stock in Novo Nordisk. Dr. Knudsen has received intellectual property interests from a discovery or technology relating to health care.
Marti Jimenez Mausbach Marti Jimenez Mausbach has received personal compensation for serving as an employee of Novo Nordisk. Marti Jimenez Mausbach has stock in Novo Nordisk.
Dylan M. Belmont-Rausch, PhD Dr. Belmont-Rausch has received personal compensation for serving as an employee of Novo Nordisk A/S. Dr. Belmont-Rausch has or had stock in Novo Nordisk.Dr. Belmont-Rausch has or had stock in Viking Therapeutics.Dr. Belmont-Rausch has or had stock in Madrigal Pharmaceuticals.
Giovanni B. Frisoni Dr. Frisoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Frisoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novo Nordisk. Dr. Frisoni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novo Nordisk. The institution of Dr. Frisoni has received research support from Novo Nordisk.
Joseph Polex-Wolf, PhD Dr. Polex-Wolf has received personal compensation for serving as an employee of Novo Nordisk A/S. Dr. Polex-Wolf has stock in Novo Nordisk.
Redwan Farooq, MB, BChir, MRCP Dr. Farooq has nothing to disclose.
Kate Attfield, MD, PhD Dr. Attfield has nothing to disclose.
Lea Y. Hildebrandt, PhD Ms. Hildebrandt has received personal compensation for serving as an employee of Novo Nordisk A/S. Ms. Hildebrandt has stock in Novo Nordisk A/S.